Skip to main
LRMR
LRMR logo

LRMR Stock Forecast & Price Target

LRMR Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Larimar Therapeutics is poised for significant growth driven by its novel CPP technology platform and the expected commercial launch of its lead product candidate, nomlabofusp, in 2026, with projections of sales reaching $356 million by 2030. The positive interim data from ongoing clinical trials indicates improvements in frataxin levels and safety profile, supporting the drug's therapeutic potential for Friedreich's ataxia, while demonstrating a promising increase in survival rates in preclinical models. The upcoming regulatory clarity and confirmatory trials scheduled for mid-2025 further strengthen Larimar’s outlook in the biotech market by potentially validating the efficacy and safety of their innovative treatment.

Bears say

Larimar Therapeutics Inc. faces significant challenges as a development-stage biotechnology company, notably its lack of profitability, which poses a considerable overhang on its stock outlook. Compounding this issue, the FDA's refusal to accept alternative surrogate endpoints for their lead product candidate creates hurdles in advancing through the regulatory process, while safety concerns regarding potential cardiac toxicity due to Frataxin overexpression present additional risks. Moreover, potential reimbursement challenges associated with high orphan drug pricing and the invasive nature of required cardiac biopsies further exacerbate the company's financial and operational uncertainties.

LRMR has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Larimar Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Larimar Therapeutics Inc (LRMR) Forecast

Analysts have given LRMR a Buy based on their latest research and market trends.

According to 10 analysts, LRMR has a Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Larimar Therapeutics Inc (LRMR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.